Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma
- PMID: 15822130
- DOI: 10.1002/cncr.21043
Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma
Abstract
Background: Portal vein thrombosis (PVT) is a common complication in patients with advanced-stage hepatocellular carcinoma (HCC). The authors evaluated the impact of radiotherapy (RT) for PVT of HCC and analyzed the dose-response relation between RT and PVT.
Methods: Between March 1995 and December 2003, 59 patients diagnosed as HCC with PVT were included. The inclusion criteria were unresectable tumor with thrombosis in the main or first branch of the portal vein, liver function of Child-Pugh Class A or B, and an Eastern Cooperative Oncology Group performance status score of 0-2. The median age of the patients was 57 years (range, 36-78 years). A daily dose ranging from 2 to 3 gray (Gy) was administered using 6 or 10-megavolt (MV) X-rays, at 5 fractions a week, to deliver a total dose range of 30-54 Gy, which was a biologic effective dose of 39-70.2 Gy(10) with an alpha/beta ratio of 10.
Results: Follow-up computed tomography scans showed a complete response (CR) in 4 of 59 patients (6.8%), a partial response (PR) in 23 patients (39.0%), no response (NR) in 28 patients (47.5%), and progressive disease (PD) in 4 patients (6.8%). The mean RT doses in the responders (CR and PR) and nonresponders (NR and PD) were 59.6 +/- 5.6 Gy(10) and 54.9 +/- 8.5 Gy(10), respectively (P = 0.036). The response rates in patients receiving < 58 Gy(10) and > or = 58 Gy(10) were 20% and 54.6%, respectively (P = 0.034). The median survival duration and the 1-year and 2-year survival rates in the responders were 10.7 months, 40.7%, and 20.7%, respectively, and were 5.3 months, 25.0%, and 4.7%, respectively, in the nonresponders (P = 0.050).
Conclusions: RT induced a 45.8% objective response rate for PVT in patients with HCC. A dose-response relation was found to exist between the RT dose and PVT response. These results suggested that RT may be a treatment option for PVT in patients with HCC and that an RT dose > or = 58 Gy(10) should be recommended.
Similar articles
-
Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable.Am J Clin Oncol. 2006 Dec;29(6):568-75. doi: 10.1097/01.coc.0000239147.60196.11. Am J Clin Oncol. 2006. PMID: 17148993 Clinical Trial.
-
[Efficacy of 3-dimensional conformal hypofractionated single high-dose radiotherapy combined with transcatheter arterial chemoembolization for portal vein tumor thrombus in patients with hepatocellular carcinoma].Ai Zheng. 2004 Jul;23(7):825-8. Ai Zheng. 2004. PMID: 15248921 Chinese.
-
Effectiveness of high-dose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis.Jpn J Clin Oncol. 2012 Aug;42(8):721-9. doi: 10.1093/jjco/hys082. Epub 2012 Jun 11. Jpn J Clin Oncol. 2012. PMID: 22689916
-
Radiation therapy for hepatocellular carcinoma: from palliation to cure.Cancer. 2006 Apr 15;106(8):1653-63. doi: 10.1002/cncr.21811. Cancer. 2006. PMID: 16541431 Review.
-
Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis.World J Gastroenterol. 2016 Aug 14;22(30):6851-63. doi: 10.3748/wjg.v22.i30.6851. World J Gastroenterol. 2016. PMID: 27570422 Free PMC article. Review.
Cited by
-
Brachytherapy with Iodine-125 seeds strand for treatment of main portal vein tumor thrombi: an experimental study in a rabbit model.Am J Cancer Res. 2016 Feb 15;6(3):587-99. eCollection 2016. Am J Cancer Res. 2016. PMID: 27152237 Free PMC article.
-
Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma.Cancers (Basel). 2024 Feb 19;16(4):838. doi: 10.3390/cancers16040838. Cancers (Basel). 2024. PMID: 38398229 Free PMC article.
-
Technical advances in external radiotherapy for hepatocellular carcinoma.World J Gastroenterol. 2016 Aug 28;22(32):7311-21. doi: 10.3748/wjg.v22.i32.7311. World J Gastroenterol. 2016. PMID: 27621577 Free PMC article. Review.
-
Should transarterial chemoembolization be given before or after intensity-modulated radiotherapy to treat patients with hepatocellular carcinoma with portal vein tumor thrombus? a propensity score matching study.Oncotarget. 2018 May 11;9(36):24537-24547. doi: 10.18632/oncotarget.25224. eCollection 2018 May 11. Oncotarget. 2018. PMID: 29849959 Free PMC article.
-
Pre-radiotherapy neutrophil-to-lymphocyte ratio as an independent prognostic factor in patients with locally advanced hepatocellular carcinoma treated with radiotherapy.Oncotarget. 2017 Mar 7;8(10):16964-16971. doi: 10.18632/oncotarget.15209. Oncotarget. 2017. PMID: 28199977 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials